Literature DB >> 32303749

Reserpine: A New Consideration of and Old Drug for Refractory Hypertension.

Matthew R Weir1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32303749      PMCID： PMC7402223          DOI： 10.1093/ajh/hpaa069

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN： 0895-7061            Impact factor:   3.080


× No keyword cloud information.
  17 in total

1.  Availability and utilization of cardiovascular fixed-dose combination drugs in the United States.

Authors:  Bo Wang; Niteesh K Choudhry; Joshua J Gagne; Joan Landon; Aaron S Kesselheim
Journal:  Am Heart J       Date:  2015-01-07       Impact factor: 4.749

2.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

3.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

4.  Antihypertensive drug side effects in the Hypertension Detection and Follow-up Program.

Authors:  J D Curb; K Schneider; J O Taylor; M Maxwell; N Shulman
Journal:  Hypertension       Date:  1988-03       Impact factor: 10.190

Review 5.  Combination drug treatment in hypertension.

Authors:  Costas Tsioufis; Costas Thomopoulos
Journal:  Pharmacol Res       Date:  2017-09-20       Impact factor: 7.658

6.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

7.  Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.

Authors:  Alejandro Velasco; Mohammed Siddiqui; Eric Kreps; Pavani Kolakalapudi; Tanja Dudenbostel; Garima Arora; Eric K Judd; Sumanth D Prabhu; Steven G Lloyd; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2018-06-04       Impact factor: 10.190

Review 8.  Treatment of Resistant and Refractory Hypertension.

Authors:  Maria Czarina Acelajado; Zachary H Hughes; Suzanne Oparil; David A Calhoun
Journal:  Circ Res       Date:  2019-03-29       Impact factor: 17.367

9.  Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study.

Authors:  Cristina Navarro-Soriano; Miguel-Angel Martínez-García; Gerard Torres; Ferrán Barbé; Candela Caballero-Eraso; Patricia Lloberes; Trinidad Diaz Cambriles; María Somoza; Juan F Masa; Mónica González; Eva Mañas; Mónica de la Peña; Francisco García-Río; Josep María Montserrat; Alfonso Muriel; Grace Oscullo; Laura Feced Olmos; Alberto García-Ortega; David Calhoun; Francisco Campos-Rodriguez
Journal:  Hypertens Res       Date:  2019-06-17       Impact factor: 3.872

Review 10.  The ins and outs of vesicular monoamine transporters.

Authors:  Dana Yaffe; Lucy R Forrest; Shimon Schuldiner
Journal:  J Gen Physiol       Date:  2018-04-17       Impact factor: 4.086
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.